Literature DB >> 10490105

The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin.

S B Lee1, K Huang, R Palmer, V B Truong, D Herzlinger, K A Kolquist, J Wong, C Paulding, S K Yoon, W Gerald, J D Oliner, D A Haber.   

Abstract

WT1 encodes a zinc finger transcription factor implicated in kidney differentiation and tumorigenesis. In reporter assays, WT1 represses transcription from GC- and TC-rich promoters, but its physiological targets remain uncertain. We used hybridization to high-density oligonucleotide arrays to search for native genes whose expression is altered following inducible expression of WT1. The major target of WT1 was amphiregulin, a member of the epidermal growth factor family. The WT1(-KTS) isoform binds directly to the amphiregulin promoter, resulting in potent transcriptional activation. The in vivo expression profile of amphiregulin during fetal kidney development mirrors the highly specific pattern of WT1 itself, and recombinant Amphiregulin stimulates epithelial branching in organ cultures of embryonic mouse kidney. These observations suggest a model for WT1 as a transcriptional regulator during kidney differentiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490105     DOI: 10.1016/s0092-8674(00)80053-7

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  53 in total

1.  Hoxa 11 is upstream of Integrin alpha8 expression in the developing kidney.

Authors:  M Todd Valerius; Larry T Patterson; Yuxin Feng; S Steven Potter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

Review 2.  Candidate genes and potential targets for therapeutics in Wilms' tumour.

Authors:  Christopher Blackmore; Max J Coppes; Aru Narendran
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

Review 3.  Wilms' tumour: a complex enigma to decipher.

Authors:  María José Robles-Frías; Michele Biscuola; María Angeles Castilla; María Angeles López-García; Felicia Sánchez-Gallego; José Palacios
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

4.  William L Gerald, M. D., Ph.D., 1954-2008.

Authors:  Marc Ladanyi
Journal:  J Mol Diagn       Date:  2009-01       Impact factor: 5.568

5.  An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1.

Authors:  Marianne K-H Kim; Thomas J McGarry; Pilib O Broin; Jared M Flatow; Aaron A-J Golden; Jonathan D Licht
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-22       Impact factor: 11.205

6.  Human antigen R-mediated mRNA stabilization is required for ultraviolet B-induced autoinduction of amphiregulin in keratinocytes.

Authors:  Hironao Nakayama; Shinji Fukuda; Natsuki Matsushita; Hisayo Nishida-Fukuda; Hirofumi Inoue; Yuji Shirakata; Koji Hashimoto; Shigeki Higashiyama
Journal:  J Biol Chem       Date:  2013-02-21       Impact factor: 5.157

7.  Par4 is a coactivator for a splice isoform-specific transcriptional activation domain in WT1.

Authors:  D J Richard; V Schumacher; B Royer-Pokora; S G Roberts
Journal:  Genes Dev       Date:  2001-02-01       Impact factor: 11.361

8.  CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.

Authors:  Chi-Ming Li; Connie E Kim; Adam A Margolin; Meirong Guo; Jimmy Zhu; Jacqueline M Mason; Terrence W Hensle; Vundavalli V V S Murty; Paul E Grundy; Eric R Fearon; Vivette D'Agati; Jonathan D Licht; Benjamin Tycko
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

9.  Expression of HIF-1, galectin-3, cox-2 and Wilms tumor-1 protein in multiple schwannomas of the conus medullaris.

Authors:  Amr M Sarwat; Suhail Al-Salam
Journal:  J Neurooncol       Date:  2008-11-09       Impact factor: 4.130

10.  RNA Binding by the KTS Splice Variants of Wilms' Tumor Suppressor Protein WT1.

Authors:  Tadateru Nishikawa; Jonathan M Wojciak; H Jane Dyson; Peter E Wright
Journal:  Biochemistry       Date:  2020-09-29       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.